Publication:
Thrombosis in breast cancer patients on cyclin-dependent kinase inhibitors: Survival impact and predictive factors - A study by the cancer and thrombosis group of the spanish society of medical oncology (SEOM)

Thumbnail Image
Files
99.Trombosis_breast_cancer.pdf(957.56 KB)
Date
2024-08-21
relationships.isAuthorOfPublication
Profile Picture
Person
Profile Picture
Person
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Adoamnei, Evdochia ; Mendiola Olivares, Jaime ; Sánchez Cánovas, Manuel ; López Robles, Javier ; Cacho Lavin, Diego ; Díaz Pedroche, Carmen ; Coma Salvans, Eva ; Quintanar Verduguez, Teresa ; García Verdejo, Francisco José ; Cejuela Solís, Mónica ; García Adrián, Silvia ; Obispo Portero, Berta ; Garrido Fernández, Alberto ; Salvador Coloma, Carmen ; Martínez del Prado, María Purificación ; Muñoz Martín, Andres J.
item.page.secondaryauthor
Facultad de Medicina ; Facultad de Enfermería
item.page.director
Publisher
Elsevier
publication.page.editor
publication.page.department
Enfermería
DOI
https://doi.org/10.1016/j.ejim.2024.08.005
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Thrombosis may be included in the profile of side effects associated with CDK4/6 inhibitors. Its significance might be greater than reported in randomized clinical trials. To investigate this, a retrospective, multicenter study was conducted. The primary objective was to calculate the incidence of thrombosis associated with CDK4/6 inhibitors. Secondary objectives included examining the impact of thrombosis on survival and identifying predictor variables for the development of venous thromboembolism (VTE) or arterial thrombosis (AT). A total of 986 patients were recruited. The incidence of VTE/AT associated with CDK4/6 inhibitor treatment during the follow-up period was 5.48 %. Survival analysis did not indicate that the development of VTE/AT during CDK4/6 inhibitor treatment significantly impacted patient survival (p = 0.133). In our analysis, two variables were found to be statistically significant (p < 0.05) as predictors of VTE/AT in breast cancer patients receiving CDK4/6 inhibitor therapy. These variables were the presence of central nervous system (CNS) metastasis with an odds ratio (OR) of 3.68 (95 % CI 1.18 - 11.49) and the use of abemaciclib with an OR of 2.3 (95 % CI 1.16 - 4.57).
publication.page.subject
Cancer-associated thrombosis , Cyclin-dependent kinase 4 and 6 inhibitor , Breast cancer
Citation
European Journal of Internal Medicine, Volume 130, 2024, Pages 98-105
URI
http://hdl.handle.net/10201/241721
item.page.embargo
Collections
Artículos
Ir a Estadísticas